PARIS (Reuters) - French drugmaker Sanofi said a late-stage Phase III trial of a drug designed to treat myelofibrosis led to positive results.
Myelofibrosis is a rare, life-threatening condition that involves abnormal blood cell production and scarring in the bone marrow.
“Patients with myelofibrosis in advanced stages are desperately ill and in need of treatments that will improve their outcomes,” Debasish Roychowdhury, head of Sanofi Oncology, said in a statement on Friday.
“Now we are planning regulatory filings with authorities to make this medicine available for patients.”
Rare disease treatments are among Sanofi’s key focuses following the acquisition of U.S. biotech Genzyme as its sales are hit by generic competition and European austerity measures.
Reporting by James Regan; Editing by David Cowell